-
Innovation Ranking
NewInnovation Ranking – Fosun International Ltd
Fosun International Ltd (Fosun) is an investment holding company, which offers asset management, insurance, industrial operations, and strategic investment services. The company, through its subsidiaries, manufactures and sells pharmaceutical and healthcare products; undertakes property development; oil and gas exploration; mining and ore processing; and makes various other investments. Fosun offers life insurance and general insurance products, wealth management services, health management service, diagnosis products, and medical devices. It invests in the retail and wholesale of gold and jewelry, entertainment and...
-
Innovation Ranking
NewInnovation Ranking – Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd, is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products are mainly applied in the treatment of metabolism and digestive system, cardiovascular system, blood system, central nervous system, anti-infection, anti-tumor, vaccine and raw material and intermediates. Fosun Pharma provides medical diagnostic products includes real time PCR detector, human papillomavirus assay kit, HBV quantitative...
-
Company Insights
Innovation and Patenting activity of Fosun International Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Fosun International Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Shanghai Fosun Pharmaceutical (Group) Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Shanghai Fosun Pharmaceutical (Group) Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XHS-003 in IgA Nephropathy (Berger’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XHS-003 in IgA Nephropathy (Berger's Disease) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XHS-003 in IgA Nephropathy (Berger's Disease) Drug Details: XHS-003 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XB-002 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XB-002 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XB-002 in Triple-Negative Breast Cancer (TNBC) Drug Details: XB-002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tegoprubart in Amyotrophic Lateral Sclerosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tegoprubart in Amyotrophic Lateral Sclerosis Drug Details: Tegoprubart is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORIN-1001 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORIN-1001 in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORIN-1001 in Metastatic Breast Cancer Drug Details: ORIN-1001 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORIN-1001 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORIN-1001 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORIN-1001 in Solid Tumor Drug Details: ORIN-1001 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORIN-1001 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORIN-1001 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORIN-1001 in Triple-Negative Breast Cancer (TNBC) Drug Details: ORIN-1001...